Cdc7 kinase - A new target for drug development

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 33-40

  Swords, Ronan ^a   Mahalingam, Devalingam ^a   O'Dwyer, Michael ^b   Santocanale, Corrado ^b   Kelly, Kevin ^a   Carew, Jennifer ^a   Giles, Francis ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Cdc7 kinase; Cell cycle; Drug development; Target

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DIVISION CYCLE PROTEIN 7; CELL DIVISION CYCLE PROTEIN 7 INHIBITOR; CYCLIN DEPENDENT KINASE; HELICASE; MINICHROMOSOME MAINTENANCE PROTEIN 2; NMS 354; PHA 767491; PROTEIN DBF4; PROTEIN DRF1; PROTEIN SERINE THREONINE KINASE; PYRROLOPYRIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL SURVIVAL; CHROMATIN STRUCTURE; CHROMOSOME SEGREGATION; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPLICATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 71049184413     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.020     Document Type: Article

References (73)

1. D'Andrea A.D., and Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3 1 (2003) 23-34
2. Michelson R.J., and Weinert T. Closing the gaps among a web of DNA repair disorders. Bioessays 22 11 (2000) 966-969
3. Coleman T.R., Carpenter P.B., and Dunphy W.G. The Xenopus Cdc6 protein is essential for the initiation of a single round of DNA replication in cell-free extracts. Cell 87 1 (1996) 53-63
4. Donovan S., et al. Cdc6p-dependent loading of Mcm proteins onto pre-replicative chromatin in budding yeast. Proc Natl Acad Sci USA 94 11 (1997) 5611-5616
5. Tanaka T., Knapp D., and Nasmyth K. Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs. Cell 90 4 (1997) 649-660
6. Jiang W., et al. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J 18 20 (1999) 5703-5713
7. Hartwell L.H. Sequential function of gene products relative to DNA synthesis in the yeast cell cycle. J Mol Biol 104 4 (1976) 803-817
8. Masai H., Miyake T., and Arai K. hsk1+, a Schizosaccharomyces pombe gene related to Saccharomyces cerevisiae CDC7, is required for chromosomal replication. EMBO J 14 13 (1995) 3094-3104
9. Bousset K., and Diffley J.F. The Cdc7 protein kinase is required for origin firing during S phase. Genes Dev 12 4 (1998) 480-490
10. Takahashi T.S., et al. Cdc7-Drf1 kinase links chromosome cohesion to the initiation of DNA replication in Xenopus egg extracts. Genes Dev 22 14 (2008) 1894-1905
11. Bailis J.M., et al. Hsk1-Dfp1 is required for heterochromatin-mediated cohesion at centromeres. Nat Cell Biol 5 12 (2003) 1111-1116
12. Bernard P., et al. Requirement of heterochromatin for cohesion at centromeres. Science 294 5551 (2001) 2539-2542
13. Nasmyth K. Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis. Annu Rev Genet 35 (2001) 673-745
14. Matos J., et al. Dbf4-dependent CDC7 kinase links DNA replication to the segregation of homologous chromosomes in meiosis I. Cell 135 4 (2008) 662-678
15. Sawa M, Masai H. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Design Develop Therapy 2008:255-64.
16. Kim J.M., et al. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint. Oncogene 27 24 (2008) 3475-3482
17. Takeda T., et al. A fission yeast gene, him1(+)/dfp1(+), encoding a regulatory subunit for Hsk1 kinase, plays essential roles in S-phase initiation as well as in S-phase checkpoint control and recovery from DNA damage. Mol Cell Biol 19 8 (1999) 5535-5547
18. Costanzo V., et al. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol Cell 11 1 (2003) 203-213
19. Dierov J., Dierova R., and Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 5 3 (2004) 275-285
20. Tenca P., et al. Cdc7 is an active kinase in human cancer cells undergoing replication stress. J Biol Chem 282 1 (2007) 208-215
21. Im J.S., and Lee J.K. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. J Biol Chem 283 37 (2008) 25171-25177
22. Kim J.M., Yamada M., and Masai H. Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. Mutat Res 532 1-2 (2003) 29-40
23. Montagnoli A., et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 64 19 (2004) 7110-7116
24. Yoshizawa-Sugata N., et al. A second human Dbf4/ASK-related protein, Drf1/ASKL1, is required for efficient progression of S and M phases. J Biol Chem 280 13 (2005) 13062-13070
25. Johnston L.H., and Thomas A.P. The isolation of new DNA synthesis mutants in the yeast Saccharomyces cerevisiae. Mol Gen Genet 186 3 (1982) 439-444
26. Chapman J.W., and Johnston L.H. The yeast gene, DBF4, essential for entry into S phase is cell cycle regulated. Exp Cell Res 180 2 (1989) 419-428
27. Wang T.S. Eukaryotic DNA polymerases. Annu Rev Biochem 60 (1991) 513-552
28. Yamada M., et al. A 63-base pair DNA segment containing an Sp1 site but not a canonical E2F site can confer growth-dependent and E2F-mediated transcriptional stimulation of the human ASK gene encoding the regulatory subunit for human Cdc7-related kinase. J Biol Chem 277 31 (2002) 27668-27681
29. Kumagai H., et al. A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells. Mol Cell Biol 19 7 (1999) 5083-5095
30. Sato N., et al. Cell cycle regulation of chromatin binding and nuclear localization of human Cdc7-ASK kinase complex. Genes Cell 8 5 (2003) 451-463
31. Masai H., and Arai K. Dbf4 motifs: conserved motifs in activation subunits for Cdc7 kinases essential for S-phase. Biochem Biophys Res Commun 275 1 (2000) 228-232
32. Montagnoli A., et al. Drf1, a novel regulatory subunit for human Cdc7 kinase. EMBO J 21 12 (2002) 3171-3181
33. Kurita M., et al. Overexpression of CR/periphilin downregulates Cdc7 expression and induces S-phase arrest. Biochem Biophys Res Commun 324 2 (2004) 554-561
34. Thalheim L.B., et al. Transcriptional regulation of the intra-S-phase regulator CDC7 in human myeloid leukemic cells: a new downstream target of the C-Myb protooncogene. ASH Annu Meeting Abstr 106 11 (2005) 1354
35. Grishina I., and Lattes B. A novel Cdk2 interactor is phosphorylated by Cdc7 and associates with components of the replication complexes. Cell Cycle 4 8 (2005) 1120-1126
36. Kiess M., Gill R.M., and Hamel P.A. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Cell Growth Differ 6 10 (1995) 1287-1298
37. Paggi M.G., et al. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62 3 (1996) 418-430
38. Suzuki-Takahashi I., et al. The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase. Oncogene 10 9 (1995) 1691-1698
39. Ohtani H., et al. Intercellular adhesion molecule-1 induction: a sensitive and quantitative marker for cardiac allograft rejection. J Am Coll Cardiol 26 3 (1995) 793-799
40. Cho W.H., et al. CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein. Proc Natl Acad Sci USA 103 31 (2006) 11521-11526
41. Montagnoli A et al. Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 2006;281(15):10281-90.
42. Vanotti E et al. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem 2008;51(3):487-501.
43. Montagnoli A., et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4 6 (2008) 357-365
44. Bonte D., et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 10 9 (2008) 920-931
45. Costanzo V., and Gautier J. Single-strand DNA gaps trigger an ATR- and Cdc7-dependent checkpoint. Cell Cycle 2 1 (2003) 17
46. Heffernan T.P., et al. Cdc7-Dbf4 and the human S checkpoint response to UVC. J Biol Chem 282 13 (2007) 9458-9468
47. Weinreich M., and Stillman B. Cdc7p-Dbf4p kinase binds to chromatin during S phase and is regulated by both the APC and the RAD53 checkpoint pathway. EMBO J 18 19 (1999) 5334-5346
48. Manke I.A., et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17 1 (2005) 37-48
49. Feng D., et al. Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells. Cancer Res 63 21 (2003) 7356-7364
50. Shreeram S., et al. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene 21 43 (2002) 6624-6632
51. Giaever G., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 6896 (2002) 387-391
52. Eissenberg J.C., et al. Cdk9 is an essential kinase in Drosophila that is required for heat shock gene expression, histone methylation and elongation factor recruitment. Mol Genet Genom 277 2 (2007) 101-114
53. Salerno D., et al. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 405 1-2 (2007) 65-78
54. Cai D., Byth K.F., and Shapiro G.I. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 66 1 (2006) 435-444
55. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 11 (2006) 1770-1783
56. Benakanakere I., et al. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 12 13 (2006) 4062-4071
57. Suggitt M., and Bibby M.C. 50 Years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11 3 (2005) 971-981
58. Tonani EA. Heterobicyclic pyrazole derivatives as a kinase inhibitors. Patent: WO2004/007504; 2004.
59. Lin EA. Substituted thiophene derivatives as anti-cancer agents. Patent: WO2005/095386; 2005.
60. Leroy EA. New imadazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular Cdc7. Patent: WO2008/046982; 2008.
61. Shafer C.M., et al. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 18 16 (2008) 4482-4485
62. Bartek J., Lukas J., and Bartkova J. Perspective: defects in cell cycle control and cancer. J Pathol 187 1 (1999) 95-99
63. Dixon H., and Norbury C.J. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 1 6 (2002) 362-368
64. Nambiar S., et al. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis 28 12 (2007) 2501-2510
65. Burger M., et al. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Brit J Cancer 96 11 (2007) 1711-1715
66. Gonzalez M.A., et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21 23 (2003) 4306-4313
67. Szelachowska J et al. Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res 2006;26(3B):2473-8.
68. Tokuyasu N., et al. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer 11 1 (2008) 37-46
69. Yang J., et al. Prognostic significance of MCM2, Ki-67, gelsolin in non-small cell lung cancer. BMC Cancer 6 (2006) 203
70. Obermann E.C., et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation, prognosis in diffuse large B-cell lymphoma: a tissue microarray, clinico-pathological analysis. BMC Cancer 5 (2005) 162
71. Wei Q., et al. Genes differentially expressed in responsive and refractory acute leukemia. Front Biosci 11 (2006) 977-982
72. Sawa M., and Hisao M. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Design Develop Therapy 2 (2008) 255-264
73. Montagnoli et al. A new and potent orally available class of Cdc7 inhibitors with anti-tumor activity. Poster presentation, 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva 2008.